Saba Malak Email

CEO, Chairman . Cytimmune Sciences

Current Roles

Employees:
9
Revenue:
$1.4M
About
CytImmune is a global leader in the field of cancer nanomedicine. The company has more than 60 issued and pending patents for its colloidal gold nanotechnology in the United States, European Union, Japan and Canada. We have successfully completed a Phase I clinical trial of CYT-6091 — the first in a series of nanomedicines based on our Aurimune nanomedicine platform. For more information about Aurimune or CytImmune, please visit our website, http://CytImmune.com. To read our opinions on topics relevant to cancer patients and their families, health care professionals, and the research community, visit our blog: http://CytImmune.Blog
Cytimmune Sciences Address
15010 Broschart Road
Rockville, MD
United States
Cytimmune Sciences Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.